Nasdaq · Biotech stocks database
AAPG — Ascentage Pharma Group International
AAPG (Ascentage Pharma Group International) stock: $15.89, $1.48B market cap, $170.8M cash, $1.56B EV, $1.61B fully diluted market cap. Next expected readout: Dec-26. Lead program: lisaftoclax (CLL/SLL), Phase 3. Data from Fully Diluted's biotech stocks database.
Overview
Assets
Pipeline
Trials
Holders
Enterprise value
$1,561.3M
Balance sheet
Cash $170.8M Debt $248.6M Net cash -$77.8M Enterprise value $1,561.3M Basic shares 93.3M shares Fully diluted shares 101.5M shares Fully diluted market cap $1,613.1M Cash per share $1.83
Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history Loading AAPG daily closes…
Loading price history…
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Now - Sep 22, 2026 Olverembatinib 20mg Phase 1 Pharmacokinetic; Olverembatinib — Jan 12 - Feb 23 APG2575 Phase 2 Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma — Feb 11 - Mar 25 lisaftoclax Phase 3 CLL/SLL — May 12 - Jun 23 Olverembatinib Phase 3 GIST — Jun 12 - Jul 24 APG -2449 Phase 1 Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid Tumor — Jul 13 - Aug 24 APG-115 Phase 1/2 Neuroblastoma; Solid Tumor — Aug 11 - Sep 22 olverembatinib Phase 3 Chronic Myeloid Leukemia; CML; CML, Chronic Phase — Sep 12 - Oct 24 Lisaftoclax (APG-2575) Phase 3 CLL/SLL — Jan 12 - Feb 23 HQP1351 Phase 1 Gastrointestinal Stromal Tumor (GIST); Solid Tumor, Adult — Jan 12 - Feb 23 APG-2449 Phase 1 Advanced Solid Cancer; Non Small Cell Lung Cancer; Esophageal Cancer — Feb 11 - Mar 24 Olverembatinib Phase 3 Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive — Feb 11 - Mar 24 APG-5918 Phase 1 Anemia — Jul 6 - Aug 17 APG-2575(Lisaftoclax ) Phase 3 Acute Myeloid Leukemia — Oct 13 - Nov 24 Lisaftoclax (APG-2575) Phase 1/2 Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy — Jul 13 - Aug 24 Lisaftoclax (APG-2575) Phase 3 Higher-risk Myelodysplastic Syndrome — Jan 12 - Feb 23 APG-3288 Phase 1 Relapsed/Refractory Hematological Malignancies; Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leu; Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Ri — Feb 7 - Mar 21 Ascentage Pharma HQP1351 bioavailable inhibitor Phase 1 Leukemia, Myeloid, Chronic; Myeloid Leukemia; Chronic Myeloid Leukemia —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets Olverembatinib
Approved · Active
Target BCR-ABL1
Indications Chronic myeloid leukemia (CML-CP with T315I; CML-AP with T315I; CML-CP resistant/intolerant to 1st/2nd-gen TKIs) (Approved) Status note Commercialized in China per this 20-F; no per-candidate target, modality, indication detail or pipeline table in the excerpts.
Lisaftoclax
Approved · Active
Target Bcl-2
Indications Relapsed/refractory CLL/SLL (adults, prior systemic therapy incl. BTK inhibitor) (Approved) Status note Commercialized in China per this 20-F; no per-candidate target, modality, indication detail or pipeline table in the excerpts.
Per-asset detail extracted from the 20-F filed 2026-04-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline Lead drug lisaftoclax Lead indication CLL/SLL Lead phase Phase 3 Active trials 26 Collaborator trials 4
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT06104566 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — CLL/SLL — NCT06640361 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — GIST — NCT06423911 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — Chronic Myeloid Leukemia; CML; CML, Chronic Phase — NCT06319456 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — CLL/SLL — NCT06051409 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive — NCT06389292 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — Acute Myeloid Leukemia — NCT06641414 Phase 3 Recruiting Sponsor Ascentage Pharma Group Inc. — Higher-risk Myelodysplastic Syndrome — NCT05147467 Phase 2 Recruiting Sponsor Ascentage Pharma Group Inc. — Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma — NCT04496349 Phase 2 Recruiting Sponsor Ascentage Pharma Group Inc. — T-Prolymphocytic Leukemia; Non-Hodgkins Lymphoma — NCT05701306 Phase 1/2 Recruiting Sponsor Ascentage Pharma Group Inc. — Neuroblastoma; Solid Tumor — NCT04501120 Phase 1/2 Recruiting Sponsor Ascentage Pharma Group Inc. — Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy — NCT04494503 Phase 1/2 Recruiting Sponsor Ascentage Pharma Group Inc. — Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma —
Sponsor-matched active trials from ClinicalTrials.gov (26 as sponsor, 4 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 30 active trials for Ascentage Pharma Group Inc. on ClinicalTrials.gov
No specialist-fund holders in 13F data for this company.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.